Cargando…

Presynaptic Release-Regulating Sphingosine 1-Phosphate 1/3 Receptors in Cortical Glutamatergic Terminals: Adaptations in EAE Mice and Impact of Therapeutic FTY720

This study provides evidence of the existence of presynaptic inhibitory sphingosine-1-phosphate receptor 1 (S1P1R) and facilitatory S1P3R in cortical nerve endings (synaptosomes) of healthy mice. The conclusion relies on the findings that (i) the S1P1R agonist CS-2100 (0.1–30 nM) inhibits the 12 mM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roggeri, Alessandra, Olivero, Guendalina, Usai, Cesare, Vanmierlo, Tim, Pittaluga, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571862/ https://www.ncbi.nlm.nih.gov/pubmed/37830557 http://dx.doi.org/10.3390/cells12192343

Ejemplares similares

Somatostatin, a Presynaptic Modulator of Glutamatergic Signal in the Central Nervous System
por: Pittaluga, Anna, et al.
Publicado: (2021)

The effect of the sphingosine‐1‐phosphate analogue FTY720 on atrioventricular nodal tissue
por: Egom, Emmanuel E., et al.
Publicado: (2015)

Presynaptic mGlu1 Receptors Control GABA(B) Receptors in an Antagonist-Like Manner in Mouse Cortical GABAergic and Glutamatergic Nerve Endings
por: Vergassola, Matteo, et al.
Publicado: (2018)

Presynaptic Release-regulating Metabotropic Glutamate Receptors: An Update
por: Olivero, Guendalina, et al.
Publicado: (2020)

Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model
por: Moon, Myung-Hee, et al.
Publicado: (2012)

Sphingosine-1-phosphate receptor-independent lung endothelial cell barrier disruption induced by FTY720 regioisomers
por: Camp, Sara M., et al.
Publicado: (2020)

Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation
por: Roggeri, Alessandra, et al.
Publicado: (2020)

FTY720, a sphingosine analog, altered placentome histoarchitecture in ewes
por: Dunlap, Kathrin A., et al.
Publicado: (2020)

Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) Attenuates Myocardial Fibrosis in Post-heterotopic Heart Transplantation
por: Ahmed, Naseer, et al.
Publicado: (2017)

The emerging role of FTY720 as a sphingosine 1‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms
por: Naseh, Maryam, et al.
Publicado: (2021)

FTY720-derivatives do not induce FTY720-like lymphopenia
por: Segura-Ulate, Ismael, et al.
Publicado: (2017)

FTY720 Story. Its Discovery and the Following Accelerated Development of Sphingosine 1-Phosphate Receptor Agonists as Immunomodulators Based on Reverse Pharmacology
por: Adachi, Kunitomo, et al.
Publicado: (2007)

Cardioprotective Effects of Sphingosine-1-Phosphate Receptor Immunomodulator FTY720 in a Clinically Relevant Model of Cardioplegic Arrest and Cardiopulmonary Bypass
por: Ahmed, Naseer, et al.
Publicado: (2019)

FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons
por: Takasugi, Nobumasa, et al.
Publicado: (2013)

S1P(1) receptor phosphorylation, internalization, and interaction with Rab proteins: effects of sphingosine 1-phosphate, FTY720-P, phorbol esters, and paroxetine
por: Martínez-Morales, Juan Carlos, et al.
Publicado: (2018)

FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells
por: Tonelli, Francesca, et al.
Publicado: (2010)

Sphingosine Kinase 2 Phosphorylation of FTY720 is Unnecessary for Prevention of Light-Induced Retinal Damage
por: Qi, Hui, et al.
Publicado: (2019)

FTY720 attenuates excitotoxicity and neuroinflammation
por: Cipriani, Raffaela, et al.
Publicado: (2015)

Anti-NMDA and Anti-AMPA Receptor Antibodies in Central Disorders: Preclinical Approaches to Assess Their Pathological Role and Translatability to Clinic
por: Olivero, Guendalina, et al.
Publicado: (2023)

Presynaptic Release-Regulating Alpha2 Autoreceptors: Potential Molecular Target for Ellagic Acid Nutraceutical Properties
por: Romeo, Isabella, et al.
Publicado: (2021)

Antinociceptive activity of the S1P-receptor agonist FTY720
por: Coste, Ovidiu, et al.
Publicado: (2008)

New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth
por: Alshaker, Heba, et al.
Publicado: (2017)

FTY720 Reduces Lipid Accumulation by Upregulating ABCA1 through Liver X Receptor and Sphingosine Kinase 2 Signaling in Macrophages
por: Tachibana, Koki, et al.
Publicado: (2022)

Presynaptic 5-HT(2A)-mGlu2/3 Receptor–Receptor Crosstalk in the Prefrontal Cortex: Metamodulation of Glutamate Exocytosis
por: Taddeucci, Alice, et al.
Publicado: (2022)

The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod
por: Patmanathan, Sathya Narayanan, et al.
Publicado: (2015)

The emerging role of FTY720 (Fingolimod) in cancer treatment
por: White, Christopher, et al.
Publicado: (2016)

Actions of FTY720 (Fingolimod), a Sphingosine-1-Phosphate Receptor Modulator, on Delayed-Rectifier K(+) Current and Intermediate-Conductance Ca(2+)-Activated K(+) Channel in Jurkat T-Lymphocytes
por: Chang, Wei-Ting, et al.
Publicado: (2020)

FTY720 postconditions isolated perfused heart by a mechanism independent of sphingosine kinase 2 and different from S1P or ischemic postconditioning
por: Vessey, Donald A., et al.
Publicado: (2013)

Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy
por: Enoru, Julius O., et al.
Publicado: (2016)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Fingolimod (FTY720), a Sphinogosine-1-Phosphate Receptor Agonist, Mitigates Choroidal Endothelial Proangiogenic Properties and Choroidal Neovascularization
por: Sorenson, Christine M., et al.
Publicado: (2022)

Nicotinic α7 receptor activation selectively potentiates the function of NMDA receptors in glutamatergic terminals of the nucleus accumbens
por: Zappettini, Stefania, et al.
Publicado: (2014)

Fingolimod (FTY720) Preserves High Energy Phosphates and Improves Cardiac Function in Heterotopic Heart Transplantation Model
por: Ahmed, Naseer, et al.
Publicado: (2020)

Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011)

Lymphocyte Modulation with FTY720 Improves Hemorrhagic Shock Survival in Swine
por: Hawksworth, Jason S., et al.
Publicado: (2012)

FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value
por: Thomson, Andrew
Publicado: (2006)

The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage
por: Stradner, Martin H, et al.
Publicado: (2011)

FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination
por: Blanc, Caroline A, et al.
Publicado: (2014)

Development and Effects of FTY720 Ophthalmic Solution on Corneal Allograft Survival
por: Liu, Zhaochuan, et al.
Publicado: (2015)

Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage
por: Xu, Hao-Liang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9vq245kg1r06ql34jvo6qpgvmt